According to Zacks, “Finch Therapeutics Group Inc. is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery(R) platform to develop a novel class of orally administered biological drugs. The company’s product candidate includes CP101, FIN-211, FIN-524 and FIN-525. Finch Therapeutics Group Inc. is based in SOMERVILLE, Mass. “
Separately, Jefferies Financial Group reduced their price objective on Finch Therapeutics Group from $29.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, April 4th.
Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) last announced its earnings results on Monday, May 16th. The company reported ($0.52) earnings per share for the quarter. Finch Therapeutics Group had a negative net margin of 448.35% and a negative return on equity of 33.13%. The firm had revenue of $0.35 million for the quarter. On average, equities research analysts expect that Finch Therapeutics Group will post -1.98 earnings per share for the current year.
Large investors have recently made changes to their positions in the company. Ancora Advisors LLC raised its position in Finch Therapeutics Group by 73.7% in the 3rd quarter. Ancora Advisors LLC now owns 6,946 shares of the company’s stock valued at $90,000 after purchasing an additional 2,946 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Finch Therapeutics Group during the fourth quarter worth $126,000. Bank of America Corp DE grew its stake in shares of Finch Therapeutics Group by 440.7% during the fourth quarter. Bank of America Corp DE now owns 14,378 shares of the company’s stock worth $143,000 after purchasing an additional 11,719 shares during the period. Qube Research & Technologies Ltd grew its stake in shares of Finch Therapeutics Group by 53.6% during the first quarter. Qube Research & Technologies Ltd now owns 37,631 shares of the company’s stock worth $189,000 after purchasing an additional 13,128 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Finch Therapeutics Group by 19.4% during the first quarter. Renaissance Technologies LLC now owns 45,000 shares of the company’s stock worth $226,000 after purchasing an additional 7,314 shares during the period. 22.68% of the stock is currently owned by institutional investors.
About Finch Therapeutics Group (Get Rating)
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.
- Get a free copy of the StockNews.com research report on Finch Therapeutics Group (FNCH)
- The Analysts Like The Fit Of Victoria’s Secret & Co
- Ambarella Is A Buy For Patient Investors
- Don’t Bet On A Big Rebound For Salesforce.com Stock
- 3 Specialty Retailers with Special Upside
- Is Roku (NASDAQ: ROKU) Bottoming Out?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.